Jazz Pharmaceuticals JAZZ Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's investment proceeds?
- Jazz Pharmaceuticals (JAZZ) reported investment proceeds of $520M in Q1 2026.
- How has Jazz Pharmaceuticals's investment proceeds changed year-over-year?
- Jazz Pharmaceuticals's investment proceeds increased by 67.7% year-over-year, from $310M to $520M.
- What is the long-term trend for Jazz Pharmaceuticals's investment proceeds?
- Over 3 years (2022 to 2025), Jazz Pharmaceuticals's investment proceeds has grown at a 183.0% compound annual growth rate (CAGR), from $60M to $1.36B.
- What does investment proceeds mean?
- Cash received from selling or maturing investments.
- How do you interpret investment proceeds?
- Higher proceeds indicate the conversion of liquid assets into cash, often used to fund operations or debt repayment.
- How does investment proceeds compare across companies?
- Standard for companies with significant cash reserves or treasury management functions.